Viewing nowVasartan 80 mg Tablet (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
White Life Science Co., Ltd.

MFDS item code 201403142 · Approved 2014.07.14 · Insurance code 625200500
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used for the treatment of essential hypertension. Additionally, it can be effectively used in patients with heart failure who are intolerant to ACE inhibitors and belong to NYHA classification II to IV. It helps to reduce the mortality risk in stable patients with left ventricular dysfunction post-myocardial infarction. It is thus widely used for hypertension management, symptom improvement in heart failure, and risk reduction after a myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this drug at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this drug once daily and do not exceed 80 mg daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug per dose orally twice daily, which may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug per dose twice daily. Over the following several weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or higher. However, do not administer this drug to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable that the daily dose of this drug not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. This drug should not be used in certain patient populations, such as those with severely impaired liver or kidney function, pregnant or potentially pregnant women, and patients allergic to this drug or its components. Elderly patients or those with elevated serum potassium levels, as well as patients with liver or cardiac diseases, should use this medication with caution and be closely monitored during administration. This drug has a blood pressure-lowering effect, and upon initial use, blood pressure may drop rapidly, which can lead to dizziness or fainting, requiring caution. Co-administration with other medications that can raise potassium levels may increase the risk of hyperkalemia, so caution is necessary when combined with these drugs. When taken with certain NSAIDs, this medication may reduce the antihypertensive effect or cause issues with kidney function, requiring caution. Pregnant or nursing mothers should avoid this medication, and if it must be taken, consultation with a doctor is necessary, and breastfeeding should be discontinued. Safety and efficacy in children and adolescents have not been fully established; therefore, its use is not recommended in these populations. In case of overdose, symptoms such as hypotension, reduced consciousness, and shock may occur, necessitating immediate medical attention. During treatment with this medication, caution is required when driving or operating machinery, as dizziness may occur. Lastly, this medication should be stored out of the reach of children, and it is advisable not to transfer it to another container.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a well-sealed container to prevent exposure to air and moisture, and kept in a cool place below 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer time.
Pale pink, round, biconvex, film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
White Life Science Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.